Medtronic announced the CE mark and international launch of the Endurant II AAA stent graft system for the treatment of abdominal aortic aneurysms through endovascular aortic repair (EVAR).
The device is indicated for the endovascular treatment of abdominal aortic aneurysms in patients with a proximal neck ≥ 10 mm in length with ≤ 60° infrarenal and ≤ 45° suprarenal angulation and in patients with a proximal aortic neck ≥ 15 mm in length with ≤ 75° infrarenal and ≤ 60° suprarenal angulation. It was developed in collaboration with more than 250 physicians from around the world.
“The Endurant II AAA stent graft system will confer considerable confidence to vascular surgeons who use EVAR to treat even the most complex abdominal aortic aneurysms,” said Hence Verhagen, chief of vascular surgery at the Erasmus Medical Center in Rotterdam, The Netherlands. “Building on the exceptional clinical outcomes of the original system, which has significantly increased the applicability of EVAR, Endurant II offers an even better user experience which will benefit even more patients whose abdominal aortic aneurysms are detected before rupturing.”
Verhagen, who led the European clinical trial of the original Endurant stent graft that contributed to that device’s approval, was the first physician to successfully use the new system since it received the CE mark.
Now available in most European counties, the Endurant II AAA stent graft system carries forward the proven performance of its predecessor, while adding three distinct enhancements to enable both the most straightforward and challenging cases:
Beginning at the point of access, the new lower-profile delivery system –– with 35% extended hydrophilic coating for enhanced access to challenging anatomies –– allows the 28mm-diameter bifurcated segment (the most commonly used size) to fit inside an 18F OD (outer diameter) catheter (down from 20F with the original device).
Second, the addition of two new contralateral limb lengths (156mm and 199mm) enables more configuration options requiring fewer total pieces.
Finally, the radiopacity of the distal end of the bifurcated segment’s contralateral gate has been improved to enhance visibility and aid with limb insertion, placement and deployment.
In the United States, the Endurant II AAA stent graft system is expected to receive approval from the US Food and Drug Administration (FDA) during 2012. The original Endurant AAA stent graft system received FDA approval in December 2010.